These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 22060015)
1. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. Konkankit VV; Kim W; Koya RC; Eskin A; Dam MA; Nelson S; Ribas A; Liau LM; Prins RM J Transl Med; 2011 Nov; 9():192. PubMed ID: 22060015 [TBL] [Abstract][Full Text] [Related]
2. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Everson RG; Antonios JP; Lisiero DN; Soto H; Scharnweber R; Garrett MC; Yong WH; Li N; Li G; Kruse CA; Liau LM; Prins RM Neuro Oncol; 2016 Mar; 18(3):368-78. PubMed ID: 26330563 [TBL] [Abstract][Full Text] [Related]
4. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Bao L; Dunham K; Lucas K Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030 [TBL] [Abstract][Full Text] [Related]
5. Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. Riccadonna C; Yacoub Maroun C; Vuillefroy de Silly R; Boehler M; Calvo Tardón M; Jueliger S; Taverna P; Barba L; Marinari E; Pellegatta S; Bassoy EY; Martinvalet D; Dietrich PY; Walker PR PLoS One; 2016; 11(8):e0162105. PubMed ID: 27579489 [TBL] [Abstract][Full Text] [Related]
6. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing. Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882 [TBL] [Abstract][Full Text] [Related]
8. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565 [No Abstract] [Full Text] [Related]
9. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937 [TBL] [Abstract][Full Text] [Related]
10. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma. Lai TJ; Sun L; Li K; Prins TJ; Treger J; Li T; Sun MZ; Nathanson DA; Liau LM; Lai A; Prins RM; Everson RG Cancer Res Commun; 2024 Jul; 4(7):1834-1849. PubMed ID: 38856710 [TBL] [Abstract][Full Text] [Related]
12. The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR). Inchakalody VP; Hydrose SP; Krishnankutty R; Merhi M; Therachiyil L; Sasidharan Nair V; Elashi AA; Khan AQ; Taleb S; Raza A; Yoosuf ZSKM; Fernandes Q; Al-Zaidan L; Mestiri S; Taib N; Bedhiafi T; Moustafa D; Assami L; Maalej KM; Elkord E; Uddin S; Al Homsi U; Dermime S Eur J Pharmacol; 2023 Apr; 945():175612. PubMed ID: 36822455 [TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma. Liu Z; Poiret T; Persson O; Meng Q; Rane L; Bartek J; Karbach J; Altmannsberger HM; Illies C; Luo X; Harvey-Peredo I; Jäger E; Dodoo E; Maeurer M Cancer Immunol Immunother; 2018 Feb; 67(2):237-246. PubMed ID: 29058035 [TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. Oi S; Natsume A; Ito M; Kondo Y; Shimato S; Maeda Y; Saito K; Wakabayashi T J Neurooncol; 2009 Mar; 92(1):15-22. PubMed ID: 19030781 [TBL] [Abstract][Full Text] [Related]
15. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Blagitko-Dorfs N; Ford LA; Naqash R; Lübbert M; Karpf AR; Nemeth MJ; Griffiths EA Oncotarget; 2016 Mar; 7(11):12840-56. PubMed ID: 26883197 [TBL] [Abstract][Full Text] [Related]
16. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. Yang D; Torres CM; Bardhan K; Zimmerman M; McGaha TL; Liu K J Immunol; 2012 May; 188(9):4441-9. PubMed ID: 22461695 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777 [TBL] [Abstract][Full Text] [Related]
18. Topotecan enhances immune clearance of gliomas. Wei J; DeAngulo G; Sun W; Hussain SF; Vasquez H; Jordan J; Weinberg J; Wolff J; Koshkina N; Heimberger AB Cancer Immunol Immunother; 2009 Feb; 58(2):259-70. PubMed ID: 18594817 [TBL] [Abstract][Full Text] [Related]
19. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407 [TBL] [Abstract][Full Text] [Related]
20. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]